SElf-SAMpling in Cervical Cancer Screening; SESAM Study

NCT ID: NCT02945891

Last Updated: 2017-04-06

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 310 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-04-30
• Study Completion Date: 2018-12-31

Brief Summary

Study aims to support development of evidence based health care in Norway through evaluating recently proposed technological improvements in cervical cancer control before their routine use. SESAM II study evaluates the accuracy of vaginal self-sampling for high risk human papillomavirus (hrHPV) testing compared with a physician-taken sample.

Detailed Description

Concept of collecting cervical cancer screening smear in home through self-sampling is new both for target population and medical professionals. Self-sampling increases screening attendance and could be an alternative to recruit more women to cervical cancer screening in Norway. As there are is an implementation ongoing to switch from cytology based screening to HPV based screening in Norway, a reliable self-sampling method for HPV testing should be available. Furthermore, detection of HPV from self-sampled specimen requires laboratory capacity and expertise to comply with quality assurance demands such as internal quality control, external quality assessment and quality improvement. National studies are crucial to obtain knowledge and build expertize among health care providers. This study aims to show non-inferior sensitivity of hrHPV testing on self-sampled vs. clinician-sampled specimens to detect high-grade cervical lesions and cancer (CIN2+). Additionally we will;

• Evaluate overall and hrHPV type specific concordance between self-taken and physician-taken samples.
• Evaluate participants views on feasibility and acceptability of self-sampling (questionnaire)
• Compare participants screening history with the questionnaire to evaluate the reason for not participating in the national screening program (if that is the case).
• Biobank biological material collected from self-sample, physician taken samples, blood and urine, for future analysis on HPV-related diseases and cancer.

Study participants will be recruited from the colposcopy referrals and cancer care units from three different hospitals. Patients with CIN 2 or CIN 3 lesions (n=200) will be recruited from Oslo University Hospital, Ullevål and Østfold Hospital Trust, while cancer patients (n=50) will be recruited from Radiumhospital.

Conditions

Cervical Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Study group

Each women recruited for the study belong to the study group. Intervention is performance of HPV testing on Evalyn®Brush and FloqSwab specimens compared to clinician-sampled specimen. Providing an urinary sample (Colli-PeeTM), blood, and a questionnaire data is optional.

Group Type: EXPERIMENTAL

HPV testing of Evalyn®Brush, FloqSwab and Colli-Pee specimens

Intervention Type: DEVICE

Each woman use the self-sampling devices in an advised order the day before they go to the hospital. There will be change of sampling order with every patient so that 50% of women will use Evalyn®Brush (Rovers Medical Devices, Oss, The Netherlands) first and 50% a FloqSwab (Coban Flock Technologies, Italy) first. In addition women are asked to provide a first void urine sample using a Colli-PeeTM (Novosanis, Belgium) on the same morning as the hospital visit. At the hospital clinician will take an additional specimen for which the performance of different self-sampling devices will be compared to.

Interventions

HPV testing of Evalyn®Brush, FloqSwab and Colli-Pee specimens

Each woman use the self-sampling devices in an advised order the day before they go to the hospital. There will be change of sampling order with every patient so that 50% of women will use Evalyn®Brush (Rovers Medical Devices, Oss, The Netherlands) first and 50% a FloqSwab (Coban Flock Technologies, Italy) first. In addition women are asked to provide a first void urine sample using a Colli-PeeTM (Novosanis, Belgium) on the same morning as the hospital visit. At the hospital clinician will take an additional specimen for which the performance of different self-sampling devices will be compared to.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Women with histological verified CIN 2 or CIN 3
• Women with histological verified cervical cancer

Exclusion Criteria

• Women with mild cervical lesions

• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Ostfold Hospital Trust

OTHER

Sponsor Role: collaborator

Oslo University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Mari Nygård

Senior Medical Officer, Head of HPV-related Epiemiological Research Unit

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Giske Ursin, MD, Prof

Role: STUDY_DIRECTOR

Oslo University Hospital, Cancer Registry of Norway

Locations

Ostfold Hospital Trust

Fredrikstad, , Norway

Oslo University Hospital, Molecular Pathology

Oslo, , Norway

Oslo University Hospital, Ullevål

Oslo, , Norway

Radiumhospital

Oslo, , Norway

Countries

Norway

References

Leinonen MK, Schee K, Jonassen CM, Lie AK, Nystrand CF, Rangberg A, Furre IE, Johansson MJ, Trope A, Sjoborg KD, Castle PE, Nygard M. Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions. J Clin Virol. 2018 Feb-Mar;99-100:22-30. doi: 10.1016/j.jcv.2017.12.008. Epub 2017 Dec 21.

Reference Type: DERIVED

PMID: 29289814 (View on PubMed)

Other Identifiers

5777899

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

2014/655

Identifier Type: -

Identifier Source: org_study_id